In preclinical studies, RTA 1701 exhibited potent inhibition of the expression of IL-17A, a key cytokine involved in the development and progression of autoimmune diseases. In a two-week study in non-human primates, RTA 1701 produced significant suppression of ex vivo stimulation of IL-17A secretion in whole blood in both a dose- and concentration-dependent manner, with significant effects observed as early as 24 hours after the first administration. In this non-human primate study, RTA 1701 also demonstrated dose-dependent systemic exposure over a broad dose range and a pharmacokinetic profile that supports once-daily oral administration. Other in vitro studies demonstrated that expression of IL-17A was significantly reduced by RTA 1701 treatment in blood samples from patients with rheumatoid arthritis and psoriasis. Additionally, RTA 1701 has demonstrated significant efficacy after oral dosing in rodent models of rheumatoid arthritis and multiple sclerosis. RTA 1701 was discovered by Reata, who holds global rights for the asset.
“We are excited to have clinical development underway with RTA 1701,” said
About RTA 1701
RTA 1701 is a selective and orally bioavailable allosteric inhibitor of RORγt, the master transcription factor that orchestrates the differentiation of T-helper 17 (Th17) cells and regulates production of pro-inflammatory cytokines, including the key effector cytokine IL-17A. The clinical significance of aberrant IL-17A signaling has been confirmed by the U.S. Food and Drug Administration’s (
Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates, bardoxolone methyl and omaveloxolone, target the important transcription factor Nrf2 that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling.
This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding the success, cost and timing of our product development activities and clinical trials, our plans to research, develop and commercialize our product candidates, and our ability to obtain and retain regulatory approval of our product candidates. You can identify forward-looking statements because they contain words such as “believes,” “will,” “may,” “aims,” “plans,” and “expects.” Forward-looking statements are based on Reata’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, (i) the timing, costs, conduct, and outcome of our clinical trials and future preclinical studies and clinical trials, including the timing of the initiation and availability of data from such trials; (ii) the timing and likelihood of regulatory filings and approvals for our product candidates; (iii) the potential market size and the size of the patient populations for our product candidates, if approved for commercial use, and the market opportunities for our product candidates; and (iv) other factors set forth in Reata’s filings with the
Vice President, Strategy
Matt Middleman, M.D.
LifeSci Public Relations
Source: Reata Pharmaceuticals, Inc.